發(fā)布時間：2017-12-26 22:25

  本文關(guān)鍵詞：扶正逐水湯聯(lián)合胸腔灌注治療肺脾氣虛型肺癌胸水的臨床觀察　出處：《成都中醫(yī)藥大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 扶正逐水湯 順鉑 胸腔灌注 臨床觀察

【摘要】：目的：通過臨床應(yīng)用,觀察扶正逐水湯聯(lián)合胸腔灌注治療肺脾氣虛型肺癌胸水的療效及安全性。方法：收集2012年10月—2013年12月成都中醫(yī)藥大學(xué)附屬醫(yī)院腫瘤科住院的符合納入標(biāo)準(zhǔn)的65例患者,將其隨機(jī)平分為治療組33例和對照組32例。對照組給予單純胸腔灌注(順鉑注射液60mg/m2+0.9%氯化鈉注射液20ml)治療,一周一次,根據(jù)情況可于7天后重復(fù),最多使用4次,末次化療后5周評價療效。治療組在此基礎(chǔ)上服用扶正逐水湯免煎中藥,每次一格,一天三次,開水沖服,一日一劑,直到末次化療結(jié)束后5周。觀察記錄兩組病例化療前后的胸水變化、KPS評分、中醫(yī)癥候療效、胃腸道反應(yīng)、血象變化等。結(jié)果：(1)經(jīng)統(tǒng)計(jì)學(xué)分析后,兩組患者在性別、年齡、胸水量、胸腔積液位置、腫瘤病理類型和治療前KPS評分上無統(tǒng)計(jì)學(xué)差異(P0.05),具有可比性；(2)兩組病例治療后胸水變化比較,治療組的總有效率高于對照組(P0.05)；(3)兩組病例治療后KPS評分比較,臨床獲益率治療組優(yōu)于對照組(P0.05)； (4)兩組病例中醫(yī)證候療效比較,兩組患者癥狀均有改善,但治療組優(yōu)于對照組(P0.05)；(5)兩組病例化療后胃腸道反應(yīng)和骨髓抑制比較,治療組較對照組少,具有統(tǒng)計(jì)學(xué)意義(P0.05),而肝(ALT/AST)腎(尿素氮和肌酐)功方面無明顯差異(P0.05)。結(jié)論：扶正逐水湯聯(lián)合胸腔灌注化療能有效治療肺癌胸腔積液。提高患者生存質(zhì)量,改善患者臨床癥狀,減輕胃腸道反應(yīng)以及骨髓抑制,但不增加副作用。臨床運(yùn)用安全有效。因此可將其作為臨床上治療肺癌胸腔積液的手段之一,為以后進(jìn)一步研究積累經(jīng)驗(yàn),為增加中醫(yī)治療肺癌胸腔積液開辟新的思路。
[Abstract]:Objective: To observe the efficacy and safety of Fuzheng Zhu Shui decoction combined with pleural perfusion in the treatment of lung and spleen qi deficiency lung cancer by clinical application. Methods: a total of 65 patients who met the inclusion criteria in the oncology department of Chengdu University of Traditional Chinese Medicine Affiliated Hospital from October 2012 to December 2013 were randomly divided into treatment group (33 cases) and control group (32 cases). The control group received simple thoracic perfusion (Cisplatin Injection 60mg/m2+0.9% Sodium Chloride Injection 20ml), once a week, according to the situation, can be repeated after 7 days, the most used 4 times, 5 weeks after the last chemotherapy, to evaluate the curative effect. The treatment group based on the use of water decoction of traditional Chinese medicine decoction of Fuzheng one by one, each style, three times a day, boiling water, one dose daily, 5 weeks after the last chemotherapy until the end. The changes of hydrothorax, KPS, TCM syndrome, gastrointestinal reaction and Hemogram were observed before and after chemotherapy in the two groups. Results: (1) after the statistical analysis, no significant difference between the two groups in gender, age, chest water, pleural effusion, pathological type and tumor location before treatment KPS score (P0.05), comparable; (2) the two groups were compared after the treatment of water change, the total efficiency of the treatment group higher than that of the control group (P0.05); (3) the two groups were compared after treatment KPS score, clinical benefit rate of the treatment group than the control group (P0.05); (4) the two groups were compared the efficacy of TCM syndrome, two patients symptoms were improved, but the treatment group than the control group (P0.05); (5) comparison inhibition of gastrointestinal reaction and bone marrow of two groups of patients after chemotherapy, the treatment group than in the control group, with statistical significance (P0.05), (ALT/AST) and liver kidney (urea and creatinine) no significant difference function (P0.05). Conclusion: Fuzheng Zhu Shui decoction combined with pleural perfusion chemotherapy can effectively treat the pleural effusion of lung cancer. Improve the patient's quality of life, improve the patient's clinical symptoms, reduce the gastrointestinal reaction and bone marrow suppression, but do not increase side effects. The clinical application is safe and effective. Therefore, it can be used as a way to treat pleural effusion of lung cancer in clinical practice. It will accumulate experience for further research and open up a new train of thought for increasing TCM treatment of lung cancer pleural effusion.
【學(xué)位授予單位】：成都中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張雪松;王琪;王利菊;;支氣管動脈灌注化療聯(lián)合胸腔灌注化療治療晚期中心型非小細(xì)胞肺癌的臨床分析[J];大連醫(yī)科大學(xué)學(xué)報(bào);2011年02期

2 林振懷;孫硯誠;冀學(xué)紅;王冬舫;;順鉑加苦參胸腔灌注聯(lián)合微波熱療治療惡性胸水的療效觀察[J];中國醫(yī)藥指南;2011年06期

3 王文武;歐陽學(xué)農(nóng);余宗陽;張霞;;射頻熱療聯(lián)合胸腔灌注化療治療惡性胸腔積液的近期療效分析[J];福州總醫(yī)院學(xué)報(bào);2006年03期

4 楊樹明;中醫(yī)辨證加胸腔灌注治療癌性胸水43例[J];中醫(yī)研究;2005年04期

5 王文武;歐陽學(xué)農(nóng);陳樟樹;余宗陽;;射頻熱療聯(lián)合胸腔灌注化療治療惡性胸腔積液的近期療效分析[J];福州總醫(yī)院學(xué)報(bào);2010年04期

6 明靜;曾銳;蔣新建;張輝;;肺癌胸腔灌注化療后胸水量的早期變化與療效的關(guān)系探討[J];西南國防醫(yī)藥;2010年07期

7 盛志紅;;胸腔灌注洛鉑與順鉑治療肺癌性胸腔積液的療效和護(hù)理[J];臨床肺科雜志;2014年04期

8 李蔚,肖邦榕;順鉑及天地欣(香菇多糖)胸腔灌注治療老年惡性胸腔積液臨床觀察[J];四川醫(yī)學(xué);2004年02期

9 畢泗允;牛艷艷;;胸腔灌注治療肺癌術(shù)后乳糜胸[J];現(xiàn)代腫瘤醫(yī)學(xué);2007年06期

10 劉先軍;彭吉霞;盧進(jìn)昌;熊暢;劉玉全;;重組人5型腺病毒胸腔灌注治療肺癌惡性胸腔積液[J];臨床肺科雜志;2010年11期

相關(guān)會議論文 前1條

1 陳偉琴;汪和美;盛華英;;沙培林胸腔灌注治療乳糜胸的護(hù)理研究[A];國家級胸部腫瘤治療護(hù)理新進(jìn)展學(xué)習(xí)班暨2013浙江省抗癌協(xié)會腫瘤護(hù)理年會論文集[C];2013年

相關(guān)碩士學(xué)位論文 前4條

1 伍安銀;扶正逐水湯聯(lián)合胸腔灌注治療肺脾氣虛型肺癌胸水的臨床觀察[D];成都中醫(yī)藥大學(xué);2015年

2 張?jiān)谙?扶正宣肺湯聯(lián)合胸腔灌注化療治療氣虛痰濕型肺癌惡性胸腔積液的臨床療效觀察[D];福建中醫(yī)藥大學(xué);2011年

3 陳飛;康萊特注射液胸腔灌注并十棗湯加味內(nèi)服治療惡性胸水的臨床觀察[D];湖北中醫(yī)藥大學(xué);2011年

4 王敘煌;CIK胸腔灌注聯(lián)合溫肺化飲法治療惡性胸腔積液的研究[D];廣州中醫(yī)藥大學(xué);2012年

，

本文編號：1339123